Skip to main content

Advertisement

Log in

Therapeutics in Huntington’s Disease

  • Cognitive Disorders (M Geschwind, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

There is no specific treatment for Huntington’s disease (HD). Its many symptoms of motor, psychiatric, and cognitive deterioration are managed with symptomatic relief, rehabilitation, and support. The only drug approved by the US Food and Drug Administration (FDA) for the treatment of HD is an antichoreic agent, tetrabenazine, but this drug is used sparingly because of uneasiness regarding its propensity to cause depression and suicidality in this population, which is already at risk for these complications. Neuroleptics are still first-line treatments for chorea accompanied by comorbid depression and/or behavioral or psychotic symptoms, as is often the case. Psychiatric features, which have a significant impact on a patient’s professional and personal life, often become the major focus of management. In addition to neuroleptics, commonly used medications include antidepressants, mood stabilizers, anxiolytics, and psychostimulants. In contrast, few treatment options are available for cognitive impairment in HD; this remains an important and largely unmet therapeutic need. HD patients typically lack insight into their disease manifestations, failing to recognize their need for treatment, and possibly even arguing against it. Multipurpose medications are employed advantageously to simplify the medication regimen, so as to facilitate compliance and not overwhelm the patient. For example, haloperidol can be prescribed for a patient with chorea, agitation, and anorexia, rather than targeting each symptom with a different drug. This approach also limits the potential for adverse effects, which can be difficult to distinguish from the features of the disease itself. With HD’s complexity, it is best managed with a multidisciplinary approach that includes a movement disorders specialist, a genetic counselor, a mental health professional, a physical therapist, and a social worker for support and coordination of services. As the disease progresses, there may be need for other specialists, such as a speech and occupational therapist, a nutritionist for weight loss, and ultimately, a palliative care specialist.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Huntington G. On chorea. Med Surg Rep. 1872;26:317–21.

    Google Scholar 

  2. The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72:971–83.

    Article  Google Scholar 

  3. Hodgson JG, Agopyan N, Gutekunst CA, et al. A YAC mouse model for Huntington’s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 1999;23:181–92.

    Article  PubMed  CAS  Google Scholar 

  4. Walker FO. Huntington’s disease. Lancet. 2007;369:218–28.

    Article  PubMed  CAS  Google Scholar 

  5. Venuto CS, McGarry A, Ma Q, Kieburtz K. Pharmacologic approaches to the treatment of Huntington’s disease. Mov Disord. 2011 Oct 13 (Epub ahead of print). This is a recent detailed review of the pharmacological aspects of the medications currently used in HD and of those being evaluated for future use.

  6. Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics. 2008;5:181–97.

    Article  PubMed  CAS  Google Scholar 

  7. Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington’s disease. Mov Disord. 2008;23:1491–504.

    Article  PubMed  Google Scholar 

  8. Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83–98.

    Article  PubMed  CAS  Google Scholar 

  9. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66:366–72.

    Article  Google Scholar 

  10. Poon LH. Role of tetrabenazine for Huntington’s disease-associated chorea. Ann Pharmacother. 2010;44:1080–9.

    Article  PubMed  CAS  Google Scholar 

  11. Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington’s disease: an open label study. Clin Neuropharmacol. 2002;25:263–5.

    Article  PubMed  CAS  Google Scholar 

  12. Squitieri F, Cannella M, Piorcellini A, et al. Shortterm effects of olanzapine in Huntington’s disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14:69–72.

    PubMed  CAS  Google Scholar 

  13. Dallocchio C, Buffa C, Tinelli C, Mazzarello P. Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol. 1999;19:101–3.

    Article  PubMed  CAS  Google Scholar 

  14. Duff K, Beglinger LJ, O’Rourke ME, et al. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington’s disease. Ann Clin Psychiatry. 2008;20:1–3.

    Article  PubMed  Google Scholar 

  15. Giménez-Roldán S, Mateo D. Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements. Neurologia. 1989;4:282–7.

    PubMed  Google Scholar 

  16. Peiris JB, Boralessa H, Lionel ND. Clonazepam in the treatment of choreiform activity. Med J Aust. 1976;1:225–7.

    PubMed  CAS  Google Scholar 

  17. Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington’s disease. Psychosomatics. 2006;47:70–2.

    Article  PubMed  Google Scholar 

  18. Saft C, Lauter T, Kraus PH, et al. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington’s Disease patients: a case series. BMC Neurol. 2006;6:11.

    Article  PubMed  Google Scholar 

  19. Holl AK, Wilkinson L, Painold A, et al. Combating depression in Huntington’s disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol. 2010;25:46–50.

    Article  PubMed  Google Scholar 

  20. Duan W, Peng Q, Masuda N, et al. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington’s disease. Neurobiol Dis. 2008;30:312–22.

    Article  PubMed  CAS  Google Scholar 

  21. Duan W, Guo Z, Jiang H, et al. Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann Neurol. 2004;55:590–4.

    Article  PubMed  CAS  Google Scholar 

  22. de Tommaso M, Specchio N, Sciruicchio V, et al. Effects of rivastigmine on motor and cognitive impairment in Huntington’s disease. Mov Disord. 2004;19:1516–8.

    Article  PubMed  Google Scholar 

  23. de Tommaso M, Difruscolo O, Sciruicchio V, et al. Two years’ follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol. 2007;30:43–6.

    Article  PubMed  Google Scholar 

  24. Cubo E, Shannon KM, Tracy D, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology. 2006;67:1268–71.

    Article  PubMed  CAS  Google Scholar 

  25. Brown GR. The use of methylphenidate for cognitive decline associated with HIV disease. Int J Psychiatry Med. 1995;25:21–37.

    Article  PubMed  CAS  Google Scholar 

  26. Brown TE, Landgraf JM. Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD. Postgrad Med. 2010;122:42–51.

    Article  PubMed  Google Scholar 

  27. Beglinger LJ, Adams WH, Paulson H, et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol. 2009;29:484–7.

    Article  PubMed  CAS  Google Scholar 

  28. Tan E, Jankovic J, Ondo W. Bruxism in Huntington’s disease. Mov Disord. 2000;15:171–3.

    Article  PubMed  CAS  Google Scholar 

  29. Burbaud P, Ducerf C, Cugy E, et al. Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. J Neurol. 2011;258:1670–5.

    Article  PubMed  CAS  Google Scholar 

  30. Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington’s disease. Parkinsonism Relat Disord. 2007;13:453–4.

    Article  PubMed  Google Scholar 

  31. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology. 2001;57:397–404.

    Google Scholar 

  32. Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG. Neurology. 2006;66:250–2.

    Article  PubMed  CAS  Google Scholar 

  33. de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. on behalf of the MermaiHD study investigators. Pridopidine for the treatment of motor function in patients with Huntington’s disease: a phase 3, randomised, placebo-controlled trial. Lancet Neurol. 2011;10:1049–57.

    Article  PubMed  Google Scholar 

  34. Zeef D, Schaper F, Vlamings R, et al. Deep brain stimulation in Huntington’s disease: the current status. Open Neurosurg J. 2011;4:7–10.

    Article  Google Scholar 

  35. Hauser RA, Furtado S, Cimino CR, et al. Bilateral human fetal striatal transplantation in Huntington’s disease. Neurology. 2002;58:687–95.

    PubMed  CAS  Google Scholar 

  36. Southwell AL, Patterson PH. Gene therapy in mouse models of Huntington disease. Neuroscientist. 2011;17:153–62.

    Article  PubMed  CAS  Google Scholar 

  37. Jongen P, Renier W, Gabreels F. Seven cases of Huntington’s disease in childhood and levodopa induced improvement in the hypokinetic—rigid form. Clin Neurol Neurosurg. 1980;82:251–61.

    Article  PubMed  CAS  Google Scholar 

  38. Striano P, Manganelli F, Boccella P, et al. Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord. 2005;20:1610–4.

    Article  PubMed  Google Scholar 

  39. de Tommaso M, Di Fruscolo O, Sciruicchio V, et al. Efficacy of levetiracetam in Huntington disease. Clin Neuropharmacol. 2005;28:280–4.

    Article  PubMed  Google Scholar 

Download references

Disclosure

Conflicts of Interest: K. Biglan is a Principal Investigator on the NINDS-sponsored study In PRE-manifest HD of CoQ10/UbiquinonE Leading to Preventive Trials (PREQUEL); he receives research funding from Lundbeck and Neurosearch and has served as a consultant for Lundbeck. A. Killoran: Clinical monitor on PREQUEL.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kevin M. Biglan MD, MPH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Killoran, A., Biglan, K.M. Therapeutics in Huntington’s Disease. Curr Treat Options Neurol 14, 137–149 (2012). https://doi.org/10.1007/s11940-012-0165-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-012-0165-x

Keywords

Navigation